IDH1 R132

P3, N=398, Not yet recruiting, NRG Oncology

P2/3, N=159, Completed, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Dec 2025 | Active, not recruiting --> Completed

P1, N=62, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027

Using stable isotope tracing to track the synthesis of S-adenosylmethionine (SAM) and acetyl-Coenzyme A (acetyl-CoA), our method reveals new insights into metabolism linked to epigenetic modifications, including glycolysis, the pentose phosphate pathway, de novo glycine synthesis, and the folate and methionine cycle. Demonstrating practical utility in case-control studies, this approach supports integrative multi-omics strategies to explore the interplay between metabolism and epigenetics across various biological systems and diseases.

Importantly, enforced nuclear actin polymerization in D-2-HG-treated cells restored lamin A expression, rescued diminished TERT levels, and decreased γH2AX; thereby suggesting a functional link between actin dynamics and nuclear state. Collectively, our findings uncover a previously unrecognized role for oncometabolite D-2-HG in modulating actin dynamics, and bridges the mechanistic gap between the structural-metabolic coupling mechanism in glioma.

Recognizing this entity is essential for accurate classification and appropriate therapeutic planning. Further studies are warranted to explore targeted therapies, including MEK inhibitors, which may hold promise based on emerging molecular data.

He received adjuvant concurrent radiation and temozolomide...We present a case of IDH-mutant astrocytoma with a somewhat atypical molecular presentation, including a previously uncharacterized IDH2 mutation, retained ATRX expression, and lack of MGMT promoter hypermethylation. Though it has not been biochemically or functionally validated, tumor methylation profiling is supportive of this previously uncharacterized IDH2 variant as tumorigenic.

P1/2, N=50, Not yet recruiting, Fundacion PETHEMA

P1, N=30, Not yet recruiting, National Cancer Institute (NCI)

F1CDx recommended FDA-approved therapies relevant to the tumor type in 41.7% of cases and tumor-agnostic or off-label therapies in 50.4%. Conclusions F1CDx profiling identified a broad spectrum of actionable alterations across diverse tumors, highlighting its strong potential to expand therapeutic options and advance precision oncology in real-world Indian practice.

P3, N=220, Recruiting, Servier Affaires Médicales | Trial completion date: Jun 2025 --> Dec 2027 | Trial primary completion date: Jun 2025 --> Dec 2027